Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

Directorate Change

September 20, 2022
RNS Number : 9534Z Renalytix PLC 20 September 2022   Renalytix plc ("Renalytix" or the "Company")   Renalytix Announces Change to Board of Directors   LONDON and SALT LAKE CITY , 20 September 2022 -   Renalytix plc   (NASDAQ: RNLX) (LSE: RENX)   announces that Ann Berman , non-executive director

Issue of shares

September 12, 2022
RNS Number : 0215Z Renalytix PLC 12 September 2022   Renalytix plc ("Renalytix" or the "Company")   Issue of shares   NEW YORK and SALT LAKE CITY , 12 September, 2022 -   Renalytix Plc   (NASDAQ: RNLX) (LSE: RENX)   announces that under the Company's Employee Share Purchase Plan (the "ESPP"),

Renalytix to Present at H.C. Wainwright Conference

September 8, 2022
RNS Number : 6200Y Renalytix PLC 08 September 2022     Renalytix   to Present at H.C. Wainwright 24th Annual Global Investment Conference   NEW YORK, NY and SALT LAKE CITY, UT    ̶  September 8, 2022   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the company will participate in a

Business update

August 17, 2022
RNS Number : 3072W Renalytix PLC 17 August 2022     This contains inside information Renalytix plc ("Renalytix" or the "Company")   Business update   NEW YORK, NY and SALT LAKE CITY, UT   August 17, 2022 (GLOBE NEWSWIRE)   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) provides the following business

Publication of clinical utility study in The AJMC

August 8, 2022
RNS Number : 1019V Renalytix PLC 08 August 2022   Renalytix plc ("Renalytix" or the "Company")   Data Results Published in American Journal of Managed Care demonstrate adoption and clinical utility of KidneyIntelX TM with Primary Care Physicians   98% of 401 Primary Care Physicians confirmed

Renalytix Reports Financial Results for Q3 of FY22

June 30, 2022
RNS Number : 7475Q Renalytix PLC 30 June 2022     Renalytix plc ("Renalytix" or the "Company")   Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2022   LONDON and SALT LAKE CITY , June 30, 2022   - Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in

Renalytix to Report Financial Results for Q3

June 23, 2022
RNS Number : 8594P Renalytix PLC 23 June 2022       Renalytix to Report Financial Results for Third Quarter Fiscal 2022 on June 30   NEW YORK and SALT LAKE CITY , June 23, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will report its third quarter fiscal 2022

Mount Sinai clinical utility data

June 10, 2022
RNS Number : 4139O Renalytix PLC 10 June 2022     Renalytix plc ("Renalytix" or the "Company")   1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX TM Risk Stratification  in Stage 1 to 3 Diabetic Kidney Disease Patients   Late-breaking data presented at American

Renalytix to Present at Growth Stock Conference

June 8, 2022
RNS Number : 0740O Renalytix PLC 08 June 2022       Renalytix to Present at 42 nd Annual William Blair Growth Stock Conference   NEW YORK and SALT LAKE CITY , June 8, 2022 -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX) today announced the Company will present at the 42 nd Annual William Blair Growth

KidneyIntelX data shows ability to assess risk

June 6, 2022
RNS Number : 6872N Renalytix PLC 06 June 2022   Renalytix plc ("Renalytix" or the "Company")   KidneyIntelX TM Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient Cohort   Data shared in oral presentation at American
Displaying 1 - 10 of 209